Review: Novel targets in the management of pneumonia
Identifieur interne : 003284 ( Main/Exploration ); précédent : 003283; suivant : 003285Review: Novel targets in the management of pneumonia
Auteurs : Luis A. Díaz [Colombie] ; Eric M. Mortensen [États-Unis] ; Antonio Anzueto [États-Unis] ; Marcos I. Restrepo [États-Unis]Source :
- Therapeutic Advances in Respiratory Disease [ 1753-4658 ] ; 2008-12.
English descriptors
- Teeft :
- Absolute risk reduction, Acute lung injury, Aeruginosa, Alfa, Alveolar macrophages, Angus, Antibiotic, Antibiotic therapy, Antimicrobial, Antimicrobial therapy, Anzueto, Apache, Arch intern, Ards, Ards network, Atypical pathogens, Aureus, Bacteremic, Bacteremic pneumococcal pneumonia, Clin, Clinical practice guidelines, Combination antibiotic therapy, Combination therapy, Communityacquired, Communityacquired pneumonia, Crit, Crit care, Cytokine, Distress syndrome, Drotrecogin, Drotrecogin alfa, Drug administration, Empiric, Ewig, First antibiotic dose, Garcia vazquez, Granulocyte factor, Guideline, Immunoadjuvant therapy, Immunomodulatory effects, Infection, Infectious diseases, Infectious diseases society, Intensive care, Intensive care unit, Intravenous, Intravenous antipseudomonal inhibitor, Laterre, Levofloxacin, Linezolid, Lung strategy, Macrolide, Macrolides, Mandell, Marrie, Mechanical ventilation, Mortensen, Mrsa, Murphy division, Niederman, Oxygenation assessment, Pathogen, Placebo, Placebo group, Pneumococcal, Pneumonia, Pneumoniae, Practice guidelines, Prowess trial, Pseudomonas, Pseudomonas aeruginosa, Randomized, Respir, Respir crit care, Respiratory disease, Respiratory tract infections, Restrepo, Risk factors, Sepsis, Septic shock, Severe pneumonia, Severe sepsis, Severity criteria, Staphylococcus, Staphylococcus aureus, Streptococcus pneumoniae, Subgroup, Syndrome, Systematic review, Systemic steroids, Texas health science center, Texas veterans health care system, Therapeutic advances, Therapy, Tidal, Tidal volume, Vancomycin, Woodhead, Wunderink.
Abstract
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.
Url:
DOI: 10.1177/1753465808098694
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F06
- to stream Istex, to step Curation: 001F06
- to stream Istex, to step Checkpoint: 000F58
- to stream Main, to step Merge: 003386
- to stream Main, to step Curation: 003284
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review: Novel targets in the management of pneumonia</title><author wicri:is="90%"><name sortKey="Diaz, Luis A" sort="Diaz, Luis A" uniqKey="Diaz L" first="Luis A." last="Díaz">Luis A. Díaz</name></author><author wicri:is="90%"><name sortKey="Mortensen, Eric M" sort="Mortensen, Eric M" uniqKey="Mortensen E" first="Eric M." last="Mortensen">Eric M. Mortensen</name></author><author wicri:is="90%"><name sortKey="Anzueto, Antonio" sort="Anzueto, Antonio" uniqKey="Anzueto A" first="Antonio" last="Anzueto">Antonio Anzueto</name></author><author wicri:is="90%"><name sortKey="Restrepo, Marcos I" sort="Restrepo, Marcos I" uniqKey="Restrepo M" first="Marcos I." last="Restrepo">Marcos I. Restrepo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:226E1AD85FC5B59B85317BDFB34F790708D49EC3</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1177/1753465808098694</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-13JBZQHW-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001F06</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F06</idno><idno type="wicri:Area/Istex/Curation">001F06</idno><idno type="wicri:Area/Istex/Checkpoint">000F58</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F58</idno><idno type="wicri:doubleKey">1753-4658:2008:Diaz L:review:novel:targets</idno><idno type="wicri:Area/Main/Merge">003386</idno><idno type="wicri:Area/Main/Curation">003284</idno><idno type="wicri:Area/Main/Exploration">003284</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Review: Novel targets in the management of pneumonia</title><author wicri:is="90%"><name sortKey="Diaz, Luis A" sort="Diaz, Luis A" uniqKey="Diaz L" first="Luis A." last="Díaz">Luis A. Díaz</name><affiliation wicri:level="1"><country xml:lang="fr">Colombie</country><wicri:regionArea>Geisinger Health System and Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá DC</wicri:regionArea><wicri:noRegion>Bogotá DC</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Mortensen, Eric M" sort="Mortensen, Eric M" uniqKey="Mortensen E" first="Eric M." last="Mortensen">Eric M. Mortensen</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>General Internal Medicine, VERDICT, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio</wicri:regionArea><wicri:noRegion>San Antonio</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Anzueto, Antonio" sort="Anzueto, Antonio" uniqKey="Anzueto A" first="Antonio" last="Anzueto">Antonio Anzueto</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio</wicri:regionArea><wicri:noRegion>San Antonio</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Restrepo, Marcos I" sort="Restrepo, Marcos I" uniqKey="Restrepo M" first="Marcos I." last="Restrepo">Marcos I. Restrepo</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Therapeutic Advances in Respiratory Disease</title><idno type="ISSN">1753-4658</idno><idno type="eISSN">1753-4666</idno><imprint><publisher>SAGE Publications</publisher><pubPlace>Sage UK: London, England</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">2</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="387">387</biblScope><biblScope unit="page" to="400">400</biblScope></imprint><idno type="ISSN">1753-4658</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1753-4658</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Absolute risk reduction</term><term>Acute lung injury</term><term>Aeruginosa</term><term>Alfa</term><term>Alveolar macrophages</term><term>Angus</term><term>Antibiotic</term><term>Antibiotic therapy</term><term>Antimicrobial</term><term>Antimicrobial therapy</term><term>Anzueto</term><term>Apache</term><term>Arch intern</term><term>Ards</term><term>Ards network</term><term>Atypical pathogens</term><term>Aureus</term><term>Bacteremic</term><term>Bacteremic pneumococcal pneumonia</term><term>Clin</term><term>Clinical practice guidelines</term><term>Combination antibiotic therapy</term><term>Combination therapy</term><term>Communityacquired</term><term>Communityacquired pneumonia</term><term>Crit</term><term>Crit care</term><term>Cytokine</term><term>Distress syndrome</term><term>Drotrecogin</term><term>Drotrecogin alfa</term><term>Drug administration</term><term>Empiric</term><term>Ewig</term><term>First antibiotic dose</term><term>Garcia vazquez</term><term>Granulocyte factor</term><term>Guideline</term><term>Immunoadjuvant therapy</term><term>Immunomodulatory effects</term><term>Infection</term><term>Infectious diseases</term><term>Infectious diseases society</term><term>Intensive care</term><term>Intensive care unit</term><term>Intravenous</term><term>Intravenous antipseudomonal inhibitor</term><term>Laterre</term><term>Levofloxacin</term><term>Linezolid</term><term>Lung strategy</term><term>Macrolide</term><term>Macrolides</term><term>Mandell</term><term>Marrie</term><term>Mechanical ventilation</term><term>Mortensen</term><term>Mrsa</term><term>Murphy division</term><term>Niederman</term><term>Oxygenation assessment</term><term>Pathogen</term><term>Placebo</term><term>Placebo group</term><term>Pneumococcal</term><term>Pneumonia</term><term>Pneumoniae</term><term>Practice guidelines</term><term>Prowess trial</term><term>Pseudomonas</term><term>Pseudomonas aeruginosa</term><term>Randomized</term><term>Respir</term><term>Respir crit care</term><term>Respiratory disease</term><term>Respiratory tract infections</term><term>Restrepo</term><term>Risk factors</term><term>Sepsis</term><term>Septic shock</term><term>Severe pneumonia</term><term>Severe sepsis</term><term>Severity criteria</term><term>Staphylococcus</term><term>Staphylococcus aureus</term><term>Streptococcus pneumoniae</term><term>Subgroup</term><term>Syndrome</term><term>Systematic review</term><term>Systemic steroids</term><term>Texas health science center</term><term>Texas veterans health care system</term><term>Therapeutic advances</term><term>Therapy</term><term>Tidal</term><term>Tidal volume</term><term>Vancomycin</term><term>Woodhead</term><term>Wunderink</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.</div></front></TEI><affiliations><list><country><li>Colombie</li><li>États-Unis</li></country></list><tree><country name="Colombie"><noRegion><name sortKey="Diaz, Luis A" sort="Diaz, Luis A" uniqKey="Diaz L" first="Luis A." last="Díaz">Luis A. Díaz</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Mortensen, Eric M" sort="Mortensen, Eric M" uniqKey="Mortensen E" first="Eric M." last="Mortensen">Eric M. Mortensen</name></noRegion><name sortKey="Anzueto, Antonio" sort="Anzueto, Antonio" uniqKey="Anzueto A" first="Antonio" last="Anzueto">Antonio Anzueto</name><name sortKey="Restrepo, Marcos I" sort="Restrepo, Marcos I" uniqKey="Restrepo M" first="Marcos I." last="Restrepo">Marcos I. Restrepo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003284 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003284 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:226E1AD85FC5B59B85317BDFB34F790708D49EC3
|texte= Review: Novel targets in the management of pneumonia
}}
| This area was generated with Dilib version V0.6.33. |  |